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aneurysm stent graft
Jonathan Sobocinski, MD, PhD, Florent Briffa, MD, Peter J.
Holt, MD, FRCS, Teresa Martin Gonzalez, MD, Rafaëlle
Spear, MD, PhD, Richard Azzaoui, MD, Blandine Maurel,
MD, PhD and Stéphan Haulon, MD, PhD
Background: Low-proﬁle (LP) stent grafts are now com-
mercially available in Europe for endovascular aortic
aneurysm repair (EVAR). In this study the midterm out-
comes and characteristics of patients treated with this last
generation of stent grafts were compared with a cohort of
patients treated with “standard-proﬁle” (SP) stent grafts.
Methods: The current study enrolled all patients treated for
elective EVAR by the SP Zenith Flex stent graft (CookMedical,
Bloomington, Ind) betweenMarch 2010 and November 2011
and patients treated for elective EVAR by the Zenith LP stent
graft (Cook Medical) between November 2011 and March
2013. All patients had a follow-up>18 months. Preoperative
computed tomography angiograms were analyzed on a
dedicated three-dimensional workstation. All data were
prospectively collected in an electronic database and retro-
spectively analyzed. A comparative study was conducted.
Results: The present study included 208 patients (107 SP
and 101 LP). Patients’ physiologic characteristics were sim-
ilar in both groups. The iliac anatomy was considered “more
challenging” in LP patients: respectively, 7% and 22% (P =
.002) of SP and LP patients had bilateral external iliac
diameter <7 mm; and 16% and 34% (P = .005) had a
combination of an external iliac diameter <7 mm and an
iliac tortuosity ratio index >1.5. No 30-day deaths were
documented. The 24-month freedom from reintervention
and overall survival rates after SP and LP were, respectively,
88% and 91% (P = .450) and 92% and 96% (P = .153). The
24-month rates for freedom from sac expansion and from
limb occlusion were 96.4% and 98.7% (P = .320) and 92%
and 95% (P = .293), respectively. One patient in each group
presented with a type I endoleak during follow-up, and two
LP patients presented with a type III endoleak (P = .235).
Conclusion: This study demonstrates that the last-gen-
eration LP stent grafts have favorable midterm outcomes
similar to SP stent grafts despite being used to treat more
patients with unfavorable iliac anatomy.*Full articles available online at www.jvascsurg.org
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http://dx.doi.org/10.1016/S1078-5884(15)00655-3Potential clinical feasibility and ﬁnancial impact of same-
day discharge in patients undergoing endovascular aortic
repair for elective infrarenal aortic aneurysm
Vincent P. Moscato, BA, Monica S. O’Brien-Irr, MS, RN,
Maciej L. Dryjski, MD, PhD, FACS, Hasan H. Dosluoglu, MD,
FACS, Gregory S. Cherr, MD, FACS and Linda M. Harris, MD,
FACS
Objective: The purpose of this study was to evaluate the
potential feasibility and ﬁnancial impact of same-day dis-
charge after elective endovascular aneurysm repair (EVAR)
for abdominal aortic aneurysm.
Methods: All elective EVARs performed between January
2012 and June 2013 were identiﬁed. Demographics,
comorbidities, complications, nursing care, ﬁnancial data,
and length of stay were analyzed.
Results: Sixty-seven (73%) EVARs were performed elec-
tively, 73% percutaneously. Intraoperative complications
were blood loss requiring transfusion (4.5%), thrombosis
(3%), femoral artery injury (1.5%), postoperative urinary
retention (4.5%), myocardial infarction (3%), respiratory
failure (1.5%), congestive heart failure (1.5%), and hemo-
dynamic or rhythm alterations (37%; evident in
88% <6 hours; 13% required therapy). Monitoring only was
needed in 28 patients (42%), intensive care in 15%. Seventy-
two percent were discharged on postoperative day one; 6%
were readmitted <30 days. Telemetry, oxygen, intravenous
hydration, and urinary catheters (routine services) were
used for shorter periods in uncomplicated patients and
those discharged on postoperative day 1. Total hospital
costs were $29,479: operating room, 80.3%; anesthesia,
2.2%; preadmission, 1%; postanesthesia unit, 3.1%; inten-
sive care unit, 1.9%; ﬂoor, 4.7%; laboratory and diagnostic
tests, 1.2%; pharmacy, 1.4%; other, 4.2%. Total cost was
similar for those discharged <20 hours or 24 to 31 hours
postoperatively (P = .51) and for monitoring only vs others
($28,146 vs $30,545; P = .12). Pharmacy ($351 vs $509; P =
.05), laboratory work ($86 vs $355; P = .01), and diagnostic
testing ($4 vs $254; P = .02) costs were lower for uncom-
plicated cases.
Conclusions: Same-day discharge is clinically feasible in
>40% of elective EVARs but requires coordination for
adequate postoperative monitoring. Signiﬁcant savings are
unlikely as most cost is operating room and device related,
and further reduction of costs in uncomplicated cases is
unlikely.
544 AbstractsA new metric for centralization of ruptured abdominal
aortic aneurysm repair in large territories
Patrice Nault, MD, Camille Brisson-Tessier, Denis Hamel,
MSc, Laurie J. Lambert, PhD and Claudia Blais, PhD
Objective: This study proposes the DEDE (Door-from-
Emergency to Door-to-EVAR [endovascular aneurysm
repair]) time as a new metric for ruptured abdominal aortic
aneurysm (RAAA) delay time to surgery, permitting coher-
ent centralization in large territories. It demonstrates how
the DEDE time can be applied, using data from the province
of Quebec, and looks at its potential effect on 30-day
mortality.
Methods: We used the Quebec Integrated Chronic Disease
Surveillance System (QICDSS), the linkage of ﬁve health
administrative databases, to build a retrospective cohort of
RAAA patients repaired operatively between April 1, 2006,
and March 31, 2013. A validated algorithm was used to
identify open surgical repair (OSR) and EVAR patients.
Hospitals performing these operations were further char-
acterized according to their location, volume of RAAA, types
of surgeries (OSR vs EVAR), and surgeon’s volume. Logistic
and log-binomial regression analyses identiﬁed the risk of
30-day mortality with age, sex, hospital volume, and surgi-
cal groups as variables. Using the DEDE 90 metric and the
attributable fraction, we projected how centralization and
increasing the number of EVAR would affect the 30-day
mortality.
Results: Among patients aged 65 years, 895 RAAAs were
identiﬁed. OSR was performed in 839 patients (93.7%) and
EVAR in 56 (6.3%). The overall 30-day mortality was 34.4%,
and more speciﬁcally, was 35.5% for OSR compared with
17.9% for EVAR (P = .0046). RAAAs were treated in 39 hos-
pitals, including 16 centers averaging less than one RAAA
repair per year. Low-volume (39.4%) vs high-volume centers
(32.5%) had similar 30-day mortality (P = .2198). In the
multivariate analysis, the relative risk for OSR was 1.95 (P =
.0211) and was not signiﬁcant for hospital volume. Applying
the DEDE 90 metric and increasing access to EVAR to 50% of
patients, the overall 30-day mortality would be 26.8%.
Conclusions: DEDE 90 is a new metric for a coherent cen-
tralization model, particularly in large territories, where
transport time is crucial. Increasing access to EVAR per-
formed in high-volume centers, with consideration to
transport time, could improve the 30-day mortality after a
RAAA repair.Modern medical treatment with or without carotid
endarterectomy for severe asymptomatic carotid
atherosclerosis
Igor Kolos, PhD, Alexandr Troitskiy, MD, Tatiana Balakho-
nova, MD, Merab Shariya, PhD, Denis Skrypnik, Tatiana
Tvorogova, PhD, Alexandr Deev, MD and Sergey Boytsov,
MD, on behalf of the Aggressive Medical Treatment Evalu-
ation for Asymptomatic Carotid Artery Stenosis (AMTEC)
Study GroupObjective: This study assessed the value of modern medical
treatment (MMT) with and without carotid endarterectomy
(CEA) in patients with asymptomatic severe carotid artery
stenosis.
Methods: We conducted a randomized trial involving 55
patients with 70% to 79% carotid stenosis at three Russian
centers. Between 2009 and 2013, 31 patients were
randomized to undergo CEA with MMT (CEA group) and 24
to receive MMT alone. The primary end point was nonfatal
ipsilateral stroke or death from any cause during a follow-up
period of 5.0 years. The secondary end point was any
nonfatal stroke, carotid revascularization, or death from any
cause during follow-up.
Results: The trial was stopped after a median follow-up of
3.3 years (maximum, 5.0 years). There were two primary
events in the CEA group and nine events in the MMT group.
The 3.3-year cumulative primary event rates were 6.5% in
the CEA group and 37.5% in the MMT group (hazard ratio
for the MMT group, 5.06; 95% conﬁdence interval, 1.53-
16.79; P = .008). The 3.3-year cumulative secondary end
point was 12.9% in the CEA group and 50.0% in the MMT
group (hazard ratio for the MMT group, 4.23; 95% con-
ﬁdence interval, 1.55-11.53; P = .0048).
Conclusions: CEA as an initial management strategy could
reduce the risk of death and major cerebrovascular events
when added to MMT.Lesion complexity drives the cost of superﬁcial femoral
artery endovascular interventions
Karen L. Walker, MD, Brian W. Nolan, MD, Jesse A. Columbo,
MD, Eva M. Rzucidlo, MD, Philip P. Goodney, MD, Daniel B.
Walsh,MD, Benjamin J. Atkinson, BA andRichard J. Powell,MD
Objective: Patients who undergo endovascular treatment of
superﬁcial femoral artery (SFA) disease vary greatly in lesion
complexity and treatment options. This study examined the
association of lesion severity and cost of SFA stenting and to
determine if procedure cost affects primary patency at 1 year.
Methods: A retrospective record review identiﬁed patients
undergoing initial SFA stenting between January 1, 2010, and
February 1, 2012. Medical records were reviewed to collect
data on demographics, comorbidities, indication for the
procedure, TransAtlantic Inter-Society Consensus (TASC) II
severity, and primary patency. The interventional radiology
database and hospital accounting database were queried to
determine cost drivers of SFA stenting. Procedure supply cost
included any item with a bar code used for the procedure.
Associations between cost drivers and lesion characteristics
were explored. Primary patency was determined using
Kaplan-Meier survival curves and a log-rank test.
Results: During the study period, 95 patients underwent
stenting in 98 extremities; of these, 61% of SFA stents were
performed for claudication, with 80% of lesions classiﬁed as
TASC II A or B. Primary patency at 1 year was 79% for the
entire cohort. The mean total cost per case was $10,333.
Increased procedure supply cost was associated with
adjunct device use, the number of stents, and TASC II
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lesions, primary patency at 1 year was similar at 80% for
high-cost (supply cost >$4000) vs 78% for low-cost (supply
cost <$4000) interventions.
Conclusions: SFA lesion complexity, as deﬁned by TASC II
severity, drives the cost of endovascular interventions but
does not appear to disadvantage patency at 1 year. Reim-
bursement agencies should consider incorporating disease
severity into reimbursement algorithms for lower extremity
endovascular interventions.The inﬂuence of cephalic vein diameter and diabetes on
primary maturation and patency of autogenous
radiocephalic arteriovenous ﬁstulas
Yang Jin Park, MD, PhD, Peter Gloviczki, MD, Young-wook
Kim, MD, PhD, Junhyuk David Kwon, MD, PhD, Dong-Ik Kim,
MD, PhD, Hye-Ryeon Jang, MD, PhD, Woo-Sung Heo, MD,
PhD and Ha-Young Oh, MD, PhD
Objective: This study identiﬁed predictors affecting matu-
ration and patency of autogenous radiocephalic arterio-
venous ﬁstulas (RCAVFs).
Methods: We retrospectively reviewed the prospectively
collected clinical data of all patients who underwent pri-
mary RCAVF creation and evaluated the effect of clinical
variables and ﬁndings of preoperative duplex ultrasoundmapping on primary maturation and patency rates of
RCAVFs.
Results: From August 2008 to December 2010, 383 vascular
access procedures were performed in 371 patients; of
these, 331 (86.4%) were autogenous AVFs, 283 (85.5%)
were primary ﬁrst AVFs, and 186 (65.7%) of these were
RCAVFs. The primary maturation rate was 88.2% at a mean
of 39  24.1 days after the operation. By multiple logistic
regression analysis, minimum cephalic vein (CV) diameter
>2 mm was an independent predictor of RCAVF maturation
(odds ratio, 3.672; 95% conﬁdence interval, 1.394-9.673; P =
.008), which was more easily achieved in nondiabetic
patients. During the mean follow-up of 47.2  23.1 months,
primary patency of RCAVFs was 80.3% at 1 year and 76.5%
at 2 years. A Cox proportional hazard model showed dia-
betes was the only independent risk factor of primary
patency (hazard ratio, 2.008; 95% conﬁdence interval,
1.022-3.945; P = .043). Nondiabetic patients with a CV
diameter >2 mm had signiﬁcantly higher primary matura-
tion rate and higher primary patency than diabetic patients
with a CV diameter 2 mm.
Conclusions: There were different risk factors affecting
RCAVF primary maturation and primary patency. A CV with
a small-diameter of 2 mm combined with diabetes was an
independent risk factor of failure not only of primary
maturation but also of primary patency in RCAVF.Selected Abstracts from the Journal of Vascular Surgery: Venous and
Lymphatic DisordersAssociation between inﬂammation biomarkers, anatomic
extent of deep venous thrombosis, and venous symptoms
after deep venous thrombosis
Anat Rabinovich, MD, Jacqueline M. Cohen, PhD, Mary
Cushman, MD and Susan R. Kahn, MD, MSc, for the BioSOX
Investigators
Objective: Inﬂammation may play a role in pathogenesis of
venous thromboembolism, but the nature of this relation-
ship is not yet understood. The objective of this study was
to assess whether inﬂammation marker levels measured at
diagnosis of deep venous thrombosis (DVT) and change in
levels during the ﬁrst month after DVT are associated with
anatomic extent of DVT and severity of venous signs and
symptoms at baseline and 1 month.
Methods: The BioSOX study is a biomarker substudy of the
Compression Stockings to Prevent the Post-Thrombotic
Syndrome (SOX) trial, a multicenter, randomized controlled
trial that included patients with a ﬁrst, acute, symptomatic,
proximal DVT. Blood samples were collected from partic-
ipants at baseline and 1 month, and C-reactive protein
(CRP), intercellular adhesion molecule 1, interleukin (IL)-6,
and IL-10 were measured by established assays. Linear
regression was used to assess the association between
continuous log-transformed baseline biomarker levels and
anatomic extent of DVT, classiﬁed as iliac or commonfemoral DVT vs femoral or popliteal DVT (reference). Pro-
portional odds ordinal logistic regression models were used
to analyze the association between biomarker level and
Villalta score (as a measure of severity of venous signs and
symptoms) at baseline and 1 month.
Results: Among 717 patients, 60.2% were male, and the
mean age was 55.2 years. There was a signiﬁcant associ-
ation between more extensive DVT (common femoral or
iliac) and levels of CRP and IL-6 at DVT diagnosis. Median
(interquartile range) CRP level was 11.6 mg/L (3.84-39.5)
in patients with common femoral or iliac DVT vs 6.86 mg/L
(3.11-22) in patients with popliteal or femoral DVT, and
median IL-6 level was 6.36 pg/mL (1.09-14.37) vs 4.40 pg/
mL (2.35-8.27), respectively. These differences were stat-
istically signiﬁcant in linear regression analyses. In addi-
tion, compared with those in the lowest quartile, each
higher quartile of baseline CRP concentration was asso-
ciated with an odds ratio of 2.89 (1.93-4.33) for having a
more severe Villalta category at baseline and 1.98 (1.28-
3.08) for having a more severe Villalta category 1 month
after DVT. Higher baseline levels of IL-6 were associated
with Villalta severity category at baseline (odds ratio, 2.40
[1.61-3.59]). Change in biomarker levels during the ﬁrst
month after DVT was not strongly associated with the
1-month Villalta score.
546 AbstractsConclusions: Levels of CRP and IL-6 at DVT diagnosis were
associated with thrombotic disease burden, as measured by
DVT extent, and severity of DVT symptoms and signs.
Further studies are required to more fully elucidate the role
of inﬂammation in DVT and its clinical course.Treatment of nutcracker syndrome with open and
endovascular interventions
Young Erben, MD, Peter Gloviczki, MD, Manju Kalra, MBBS,
Haraldur Bjarnason, MD, Nanette R. Reed, MD, Audra A.
Duncan, MD, Gustavo S. Oderich, MD, and Thomas C.
Bower, MD
Objective: Nutcracker syndrome (NS) is a rare cause of
hematuria, ﬂank pain, and renal venous hypertension due
to compression of the left renal vein (LRV) between the
aorta and the superior mesenteric artery. To evaluate out-
comes of open surgery and endovascular interventions, we
reviewed our experience.
Methods: A retrospective review of clinical data of all
patients treated at our institution with an intervention for
NS between January 1, 1994, and February 28, 2014, was
performed. Primary outcomes were morbidity and mortal-
ity. Secondary outcomes included late complications,
patency, freedom from reintervention, and resolution of
symptoms.
Results: Thirty-seven patients (30 female, seven male) with
a mean age of 27 years (range, 14-62 years) were treated.
The most frequent symptom was ﬂank pain (97%); the most
frequent sign was hematuria (68%). NS was diagnosed with
duplex ultrasound scanning with measurement of LRV
diameters and ﬂow velocities (87%), with computed
tomography or magnetic resonance venography (94%), andwith contrast venography with measurement of pressure
gradients (93%). Initial treatment was open surgery in 36
patients, endovascular in 1. Distal transposition of the LRV
into the inferior vena cava (IVC) was performed in 31
patients. Adjunctive procedures to optimize venous outﬂow
included great saphenous vein cuff in six patients, great
saphenous vein patch in four, and both cuff and patch in
four. Three patients had patch alone; two had transposition
of the left gonadal vein into the IVC. Two patients had
anterior reimplantation of retroaortic LRV into the IVC.
There were no major early complications, renal failure, or
mortality. Three patients underwent early reinterventions
within 30 days (stent, two; open revision, one). All LRVs and
left gonadal veins were patent at discharge. Follow-up was
36.8  52.6 months (range, 1-216 months). Reinterventions
after 30 days were performed in eight patients because of
LRV stenosis (n = 7) or LRV occlusion (n = 1). One stent
migrated into the IVC and required endovascular removal
with repeated stenting. Six patients required stenting.
Primary, primary assisted, and secondary patencies at
24 months were 74%, 97%, and 100%, respectively. Free-
dom from reintervention at 12 and 24 months was 76% and
68%, respectively. Resolution of symptoms occurred in 33
patients (87%).
Conclusions: Open surgery, mostly LRV transposition,
remains a safe and effective treatment of patients with NS.
However, one of three patients after open repair required
reintervention, most frequently LRV stenting. Open recon-
struction should be tailored to the patient’s anatomy, and
placement of vein cuff or patch may reduce restenosis.
Although renal vein stents improved patency, the safety and
durability of currently available stents need to be
established.
